Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
- Shun Ishibashi,
- Hidenori Arai,
- Koutaro Yokote,
- Eiichi Araki,
- Hideki Suganami,
- Shizuya Yamashita,
J Clin Lipidol 2018 Jan - Feb;12(1):173-184. Epub 2017 Oct 28.
Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan; Department of Cardiovascular Medicine, Rinku General Medical Center, Izumisano, Japan.